Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 467-473 , May 2008

Cerebral kinetics of the dopamine D2 receptor ligand [123I]IBZM in mice

  • Philipp T. Meyer

      Affiliations

    • Department of Neurology, University Hospital Aachen, 52074 Aachen, Germany
    • Department of Nuclear Medicine, University Hospital Aachen, 52074 Aachen, Germany
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, University Hospital Aachen, 52074 Aachen, Germany. Tel.: +49 241 8088743; fax: +49 241 8082520.
    • ,
  • Dagmar Salber

      Affiliations

    • C. & O. Vogt Institute of Brain Research, University Hospital Duesseldorf, 40225 Duesseldorf, Germany
    • ,
  • Johannes Schiefer

      Affiliations

    • Department of Neurology, University Hospital Aachen, 52074 Aachen, Germany
    • ,
  • Markus Cremer

      Affiliations

    • Institute of Neurosciences and Biophysics, Research Center Juelich, 52425 Juelich, Germany
    • ,
  • Wolfgang M. Schaefer

      Affiliations

    • Department of Nuclear Medicine, University Hospital Aachen, 52074 Aachen, Germany
    • ,
  • Christoph M. Kosinski

      Affiliations

    • Department of Neurology, University Hospital Aachen, 52074 Aachen, Germany
    • ,
  • Karl-Josef Langen

      Affiliations

    • Institute of Neurosciences and Biophysics, Research Center Juelich, 52425 Juelich, Germany

Received 29 November 2007 ,Revised 4 January 2008 ,Accepted 30 January 2008.

References 

  1. Meyer PT, Circiumaru V, Cardi CA, Thomas DH, Bal H, Acton PD. Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function. Eur J Nucl Med Mol Imaging. 2006;33:948–954
  2. Acton PD, Choi SR, Plossl K, Kung HF. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:691–698
  3. Acton PD, Hou C, Kung MP, Plossl K, Keeney CL, Kung HF. Occupancy of dopamine D2 receptors in the mouse brain measured using ultra-high-resolution single-photon emission tomography and [123]IBF. Eur J Nucl Med Mol Imaging. 2002;29:1507–1515
  4. Saji H, Iida Y, Kawashima H, Ogawa M, Kitamura Y, Mukai T, et al. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal Sci. 2003;19:67–71
  5. Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstatter M, Stefanova N, et al. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. Neuroimage. 2005;24:822–831
  6. Vastenhouw B, Beekman F. Submillimeter total-body murine imaging with U-SPECT-I. J Nucl Med. 2007;48:487–493
  7. Kung HF, Guo YZ, Billings J, Xu X, Mach RH, Blau M, et al. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Int J Rad Appl Instrum B. 1988;15:195–201
  8. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, et al. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem. 1994;37:1558–1561
  9. Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC, et al. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse. 1999;31:134–139
  10. Gouhier C, Chalon S, Venier-Julienne MC, Bodard S, Benoit J, Besnard J, et al. Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide. Neurosci Lett. 2000;288:71–75
  11. Nikolaus S, Larisch R, Wirrwar A, Jamdjeu-Noune M, Antke C, Beu M, et al. [123I]Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine — an in vivo imaging study with a dedicated small animal SPECT. Eur J Nucl Med Mol Imaging. 2005;32:1305–1310
  12. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87:493–506
  13. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A. 1998;95:6480–6485
  14. Brucke T, Tsai YF, McLellan C, Singhanyom W, Kung HF, Cohen RM, et al. In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT. Life Sci. 1988;42:2097–2104
  15. Singhaniyom W, Tsai YF, Brucke T, McLellan CA, Cohen RM, Kung HF, et al. Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist. Brain Res. 1988;453:393–396
  16. Slifstein M, Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol. 2001;28:595–608
  17. Camps M, Kelly PH, Palacios JM. Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species. J Neural Transm Gen Sect. 1990;80:105–127
  18. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–1539
  19. Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, et al. In vitro and in vivo D2-dopamine receptor binding with [123I]S()) iodobenzamide ([123I]IBZM) in rat and human brain. Int J Rad Appl Instrum B. 1991;18:837–846
  20. Matsumura K, Toyama H, Nakashima H, Ichise M, Kurami M, Nakagawa T, et al. In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties. Kaku Igaku. 1994;31:513–519[Japanese]
  21. Toyama H, Matsumura K, Nakashima H, Ichise M, Kurami M, Nakagawa T, et al. In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of D2 dopamine receptors — a basis for semiquantitative measurement of the receptor density using equilibrium analysis. Kaku Igaku. 1994;31:1117–1120[Japanese]
  22. Li H, Gildehaus FJ, Dresel S, Patt JT, Shen M, Zhu T, et al. Comparison of in vivo dopamine D2 receptor binding of [(123)I]AIBZM and [(123)I]IBZM in rat brain. Nucl Med Biol. 2001;28:383–389
  23. Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, et al. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med. 1989;30:88–92
  24. Nadeau SE, Couch MW, Devane CL, Shukla SS. Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. J Nucl Med. 1995;36:384–393
  25. Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med. 2003;44:839–845
  26. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36:1182–1190
  27. Kessler RM, Ansari MS, de Paulis T, Schmidt DE, Clanton JA, Smith HE, et al. High affinity dopamine D2 receptor radioligands: 1. Regional rat brain distribution of iodinated benzamides. J Nucl Med. 1991;32:1593–1600
  28. Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J Nucl Med. 1990;31:648–654
  29. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986;231:258–261
  30. Ito H, Hie tala J, Blomqvist G, Halldin C, Farde L. Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab. 1998;18:941–950
  31. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab. 1993;13:24–42
  32. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999–1006
  33. Opacka-Juffry J, Ahier RG, Cremer JE. Nomifensine-induced increase in extracellular striatal dopamine is enhanced by isoflurane anaesthesia. Synapse. 1991;7:169–171
  34. Seeman P, Kapur S. Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. Synapse. 2003;50:35–40
  35. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N, et al. Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res. 1999;849:85–96
  36. Lenz C, Rebel A, van Ackern K, Kuschinsky W, Waschke KF. Local cerebral blood flow, local cerebral glucose utilization, and flow-metabolism coupling during sevoflurane versus isoflurane anesthesia in rats. Anesthesiology. 1998;89:1480–1488
  37. Okamoto H, Meng W, Ma J, Ayata C, Roman RJ, Bosnjak ZJ, et al. Isoflurane-induced cerebral hyperemia in neuronal nitric oxide synthase gene deficient mice. Anesthesiology. 1997;86:875–884
  38. Thompson JS, Brown SA, Khurdayan V, Zeynalzadedan A, Sullivan PG, Scheff SW. Early effects of tribromoethanol, ketamine/xylazine, pentobarbitol, and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice. Comp Med. 2002;52:63–67
  39. Watkins JB, Engles DR, Beck LV. Effect of volatile anesthetics on the hepatic UDP-glucuronic acid pathway in mice. Biochem Pharmacol. 1990;40:731–735
  40. Buzaleh AM, Enriquez de Salamanca R, del Carmen Batlle AM. Administration of the anesthetic isoflurane to mice: a model for acute intermittent porphyria?. J Pharmacol Toxicol Methods. 1992;28:191–197

PII: S0969-8051(08)00035-8

doi: 10.1016/j.nucmedbio.2008.01.002

Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 467-473 , May 2008

Article Tools

* Image Usage & Resolution